Researchers examined whether the difference in the circulating levels of each brain natriuretic peptide molecular form is related to the incidence of worsening renal function in acute heart failure.
County-level poverty is strongly associated with heart failure and CHD mortality, and the correlation is stronger for heart failure mortality.
Mortality rate trends for newly diagnosed heart failure patients indicate that the overall reduction in mortality across all age groups is being hindered by high and increasing rates of noncardiovascular events.
Cancer survivors face an increase in the long-term risk for cardiovascular disease.
Patients with congenital heart disease had higher rates of any in-hospital event, length of stay 7 days or longer, and incident arrhythmia.
Persons living with HIV who are hospitalized with heart failure are at an increased risk for subsequent sudden cardiac death.
For patients with heart failure, type 2 diabetes is associated with structural changes in the heart, poorer quality of life, and increased mortality.
The FDA has approved the Barostim Neo System (CVRx, Inc.) for the improvement of symptoms of heart failure.
Dapagliflozin significantly reduced the risk of cardiovascular death or worsening heart failure when added to standard of care treatment in patients with reduced ejection fraction.
Maintenance dose of levothyroxine does not differ in patients with hypothyroidism with vs without heart failure.
